A comparative-effectiveness analysis applying a 3 way propensity matching to real-world data from MSBase Registry in preparation for a cost effectiveness model: patients switching within firstline agents or to natalizumab or fingolimod in active RRMS


Spelman T., Havrdova E., Horakova D., Trojano M., Lugaresi A., Izquierdo G., ...Daha Fazla

7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, Fransa, 25 - 28 Ekim 2017, cilt.23, ss.395-397 identifier

  • Yayın Türü: Bildiri / Özet Bildiri
  • Cilt numarası: 23
  • Basıldığı Şehir: Paris
  • Basıldığı Ülke: Fransa
  • Sayfa Sayıları: ss.395-397